References
- The Antibody Society. Therapeutic monoclonal antibodies approved or in review in the EU or the US. [accessed 2024 May 16]. https://www.antibodysociety.org/resources/approved-antibodies/.
- Gellene D. Immunex says enbrel shortage worse than anticipated [Internet]. Los Angeles Times; 2002. https://www.latimes.com/archives/la-xpm-2002-may-24-fi-immunex24-story.html.
- Kshirsagar R, Ryll T. Innovation in cell banking, expansion, and production culture. Adv Biochem Eng Biotechnol 2018;165:51–5.
- Kelley B. Very large scale monoclonal antibody purification: the case for conventional unit operations. Biotechnol Progr. 2007;23:995–1008.
- Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. Downstream processing of monoclonal antibodies—application of platform approaches. J Chromatogr B. 2007;848(1):28–39. doi:10.1016/j.jchromb.2006.09.026.
- Kelley B. Industrialization of mAb production technology: the bioprocessing industry at a crossroads. Mabs-austin. 2009;1(5):443–52. doi:10.4161/mabs.1.5.9448.
- Ecker DM, Seymour P. Supply and demand trends: mammalian biomanufacturing industry overview. Bioprocess international [Internet]. 2020. https://www.bioprocessintl.com/economics/supply-and-demand-trends-mammalian-biomanufacturing-industry-overview.
- Kelley B. Developing therapeutic monoclonal antibodies at pandemic pace. Nat Biotechnol. 2020;38(5):540–45. doi:10.1038/s41587-020-0512-5.
- Xu J, Ou J, McHugh KP, Borys MC, Khetan A. Upstream cell culture process characterization and in-process control strategy development at pandemic speed. Mabs-austin. 2022;14(1):2060724. doi:10.1080/19420862.2022.2060724.
- Zhang Z, Chen J, Wang J, Gao Q, Ma Z, Xu S, Zhang L, Cai J, Zhou W. Reshaping cell line development and CMC strategy for fast responses to pandemic outbreak. Biotechnol Progr. 2021;37(5):e3186. doi:10.1002/btpr.3186.
- Jones BE, Brown-Augsburger PL, Corbett KS, Westendorf K, Davies J, Cujec TP, Wiethoff CM, Blackbourne JL, Heinz BA, Foster D. et al. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021;13(593):eabf1906. doi:10.1126/scitranslmed.abf1906.
- Kelley B, Moor PD, Douglas K, Renshaw T, Traviglia S. Monoclonal antibody therapies for COVID-19: lessons learned and implications for the development of future products. Curr Opin Biotechnol. 2022;78:102798. doi:10.1016/j.copbio.2022.102798.
- Agostinetto R, Rossi M, Dawson J, Lim A, Simoneau MH, Boucher C, Valldorf B, Ross-Gillespie A, Jardine JG, Sok D. et al. Rapid cGMP manufacturing of COVID-19 monoclonal antibody using stable CHO cell pools. Biotechnol Bioeng. 2021;119(2):663–666.
- Lehman A, Muñiz VA, Chaney R, Pimentel J, Mattila J, Lawrence S. Speed and need: twin development challenges in rapid response for a SARS-CoV-2 antibody cocktail. Curr Opin Biotechnol. 2022;76:102715. doi:10.1016/j.copbio.2022.102715.
- Deeks ED. Casirivimab/Imdevimab: first approval. Drugs. 2021;81(17):2047–55. doi:10.1007/s40265-021-01620-z.
- Rhee A, Bonacci TM, Stanley B, Evangelist G, Fisher J, Armando, J, Maa Y-F, Ladiwala A, Dowd CJ, Deitcher R, et al. Rapid filter or resin change strategies for biomanufacturing. Pharm Eng. 2023;43(1): 55–60.
- Kelley B, Renshaw T, Kamarck M. Process and operations strategies to enable global access to antibody therapies. Biotechnol Progr. 2021;37(3):e3139. doi:10.1002/btpr.3139.
- IAVI. Expanding access to monoclonal antibody-based products: a global call to action [Internet]. [accessed 2020 Aug 26]. https://www.iavi.org/news-resources/expanding-access-to-monoclonal-antibody-based-products-a-global-call-to-action.
- Sparrow E, Friede M, Sheikh M, Torvaldsen S. Therapeutic antibodies for infectious diseases. Bull World Health Organ. 2017;95(3):235–37. doi:10.2471/BLT.16.178061.
- Marston HD, Paules CI, Fauci AS. Monoclonal antibodies for emerging infectious diseases — borrowing from history. N Engl J Med. 2018;378(16):1469–72. doi:10.1056/NEJMp1802256.
- Kamarck ME. Building biomanufacturing capacity—the chapter and verse. Nat Biotechnol. 2006;24(5):503–05. doi:10.1038/nbt0506-503.
- Hurlburt NK, Seydoux E, Wan Y-H, Edara VV, Stuart AB, Feng J, Suthar MS, McGuire AT, Stamatatos L, Pancera M. Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation. Nat Commun. 2020;11(1):5413. doi:10.1038/s41467-020-19231-9.
- Wang X, Mathieu M, Brezski RJ. IgG Fc engineering to modulate antibody effector functions. Protein Cell. 2017;9(1):63–73. doi:10.1007/s13238-017-0473-8.
- Cain P, Huang L, Tang Y, Anguiano V, Feng Y. Impact of IgG subclass on monoclonal antibody developability. Mabs-austin. 2023;15(1):2191302. doi:10.1080/19420862.2023.2191302.
- Zarzar J, Khan T, Bhagawati M, Weiche B, Sydow-Andersen J, Sreedhara A. High concentration formulation developability approaches and considerations. mAbs. 2023;15(1):2211185. doi:10.1080/19420862.2023.2211185.
- Dai J, Izadi S, Zarzar J, Wu P, Oh A, Carter PJ. Variable domain mutational analysis to probe the molecular mechanisms of high viscosity of an IgG1 antibody. Mabs-austin. 2024;16(1):2304282. doi:10.1080/19420862.2024.2304282.